We use leading edge science to target the root causes of inflammation. See How Our Programs We are building a broad portfolio with best-in-class potential. See Our Pipeline Recent News March 17, 2025 Evommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patie...